Novel chondroitin sulfate having decreased molecular weight and use thereof

a chondroitin sulfate and molecular weight technology, applied in the direction of drug compositions, antinoxious agents, extracellular fluid disorder, etc., can solve the problems of deterioration of peritoneal function, poor water removal or insufficient removal of waste products, and achieve the effect of reducing molecular weigh

Inactive Publication Date: 2010-11-11
SEIKAGAKU KOGYO CO LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]According to the present invention, a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of

Problems solved by technology

However, in recent years, various disorders due to prolonged peritoneal dialysis, for example, poor water removal or

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel chondroitin sulfate having decreased molecular weight and use thereof
  • Novel chondroitin sulfate having decreased molecular weight and use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Chondroitin Sulfate Having Decreased Molecular Weight of the Present Invention (1)

[0027]Prionace glauca-derived chondroitin sulfate C (weight average molecular weight: 30 kDa, trade name of Seikagaku Corporation: Chondroitin sulfate C, sodium salt (shark cartilage), SG) was used as a starting material and dissolved in an amount of 1 g in 50 mL of PBS (pH 5.3). To this solution, 100,000 U of ovine testicular hyaluronidase (manufactured by Sigma, type V) was added, and the enzymatic reaction was allowed to proceed at 37 ° C. A portion of the reaction mixture was taken over time and analyzed by GPC-HPLC to examine the degree of reduction of the molecular weight. When a desired molecular weight was obtained, the reaction mixture was boiled to stop the enzymatic reaction. In the case where the desired molecular weight was not obtained, ovine testicular hyaluronidase was further added to the reaction mixture and the enzymatic reaction was allowed to proceed. When the desire...

example 2

Preparation of Chondroitin Sulfate Having Decreased Molecular Weight of the Present Invention (2)

[0029]Prionace glauca-derived chondroitin sulfate C (weight average molecular weight: 30 kDa, trade name of Seikagaku Corporation: Chondroitin sulfate C, sodium salt (shark cartilage), SG) was used as a starting material and subjected to electron beam irradiation at an irradiation energy of 200 kGy according to the method described in JP-A-2004-43645, whereby a chondroitin sulfate having a decreased molecular weight of the present invention having a weight average molecular weight of 10 kDa and containing a constituent disaccharide unit represented by -[4GlcAβ1-3GalNAc(6S)β1]- (wherein GlcA represents a D-glucuronic acid residue; GalNAc represents an N-acetyl-D-galactosamine residue; p1-3 represents a β1-3 glycosidic linkage; β1-4 represents a β1-4 glycosidic linkage; and (6S) indicates that position 6 of the monosaccharide residue is sulfated) in an amount of 73.0% (molar ratio) of the ...

example 3

Effect of Protecting Peritoneum in Peritoneal Dialysis of Chondroitin Sulfate Having Decreased Molecular Weight of the Present Invention (1)

(Experimental Method)

[0030]To a Wistar male rat at 8 weeks of age, Midpeliq 250 (trade name, a peritoneal dialysis fluid containing glucose at a concentration of 2.5% (w / v) manufactured by Terumo Corporation) in which a test substance was dissolved at a concentration of 0.1% (w / v) was repetitively administered into the peritoneal cavity once daily at 15 mL / body for 7 days under ether anesthesia. To a control group (Control), Midpeliq 250 was administered in the same manner. On the next day after the final administration, a peritoneal equilibration test was performed, and the peritoneal function was evaluated. To be more specific, Midpeliq 250 was injected into the peritoneal cavity at 60 mL / kg, and 4 hours thereafter, the fluid remaining in the peritoneal cavity was recovered. The amount of the recovered fluid was measured, and the ultrafiltrati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to view more

Abstract

An object of the present invention is to provide a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65 o to 100% (molar ratio) of the total.
-[4GlcAβ1-3GalNAc(6S)β1]-
(wherein GlcA represents a D-glucuronic acid residue; GalNAc represents an N-acetyl-D-galactosamine residue; β1-3 represents a β1-3 glycosidic linkage; β1-4 represents a β1-4 glycosidic linkage; and (6S) indicates that position 6 of the monosaccharide residue is sulfated)

Description

TECHNICAL FIELD [0001]The present invention relates to a novel chondroitin sulfate having a decreased molecular weight and use thereof. More particularly, the present invention relates to a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like, and use thereof.BACKGROUND ART [0002]Artificial dialysis for patients with end-stage renal failure is broadly divided into hemodialysis and peritoneal dialysis. Among these, the peritoneal dialysis is a method in which a hypertonic dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent is injected into the peritoneal cavity and excess waste products, water, and electrolytes in the body are removed with the use of the function of the peritoneum as a semiperme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/715C08B37/08A61P7/02
CPCA61K31/726A61K31/737A61M1/287C08B37/0069C08J3/28C08J2305/08C08L5/08C08K3/02C08K3/08C08K5/09A61P13/12A61P39/06A61P43/00A61P7/02A61P7/08
Inventor KOJIMA, KAZUHIROGOTO, YUKIOMAEDA, HIROSHI
Owner SEIKAGAKU KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap